Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 13, Issue 1 (Vol.13 No.1 Apr 2024)
rbmb.net 2024, 13(1): 23-30 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Musa Sultan M, Hussein Abdullah T, Abbas Abdullah M, Al-Darkazali W, Sattar Harbi N. Evaluate the Serum of Irisin, Omentin-1, and Oxidative Status in Males with Prostatic Cancer. rbmb.net 2024; 13 (1) :23-30
URL: http://rbmb.net/article-1-1363-en.html
URL: http://rbmb.net/article-1-1363-en.html
Malik Musa Sultan 
, Talib Hussein Abdullah , Mohammed Abbas Abdullah , Waleed Al-Darkazali , Nazar Sattar Harbi *
, Talib Hussein Abdullah , Mohammed Abbas Abdullah , Waleed Al-Darkazali , Nazar Sattar Harbi *
College of Science, Mustansiriyah University, Palestine Street, Baghdad, Iraq.
Abstract: (708 Views)
Background: Prostate cancer is a classic public health problem in males and has broadly different levels of mortality and morbidity. As an endocrine gland, adipose tissue synthesizes and secretes a variety of bioactive peptides, such as irisin and omentin-1. Adipokines and oxidative stress potentially contribute to the proliferation of prostatic carcinoma cells. The relationship between irisin, omentin-1, and oxidative stress has not been widely investigated in prostate cancer. Therefore, the present research assessed whether there is a significant correlation between irisin and omentin-1 levels and oxidative status in prostate cancer individuals.
Methods: The present research recruited 40 individuals diagnosed with prostate cancer and 40 healthy individuals for comparative purposes. All individuals underwent demographics, biochemicals, and serum adipokines (irisin and omentin-1) data analysis.
Results: The means of total prostate-specific antigen (43.3±20.5 vs. 2.5±1.2) and free prostate-specific antigen (2.1±1.4 vs. 0.08±0.02) were highly significant increases in the prostate cancer patients than in the healthy individuals. Furthermore, the means of omentin-1 (31.6±12.8 vs. 23.5±14.1) and total oxidant stress (22.4±10.6 vs. 9.1±3.6) were highly significant increases in patients with prostate cancer than in healthy individuals. In contrast, the means of irisin (343.5±240.2 vs. 716.4±142.3) and total antioxidant capacity (2.2±1.2 vs. 3.3±1.3) were highly significant decreases in patients with prostate cancer than in healthy individuals. No significant relationship was demonstrated between all parameters in the two groups under study.
Conclusion: The study findings indicate that irisin and omentin-1 could serve as biomarkers for predicting prostate cancer.
Methods: The present research recruited 40 individuals diagnosed with prostate cancer and 40 healthy individuals for comparative purposes. All individuals underwent demographics, biochemicals, and serum adipokines (irisin and omentin-1) data analysis.
Results: The means of total prostate-specific antigen (43.3±20.5 vs. 2.5±1.2) and free prostate-specific antigen (2.1±1.4 vs. 0.08±0.02) were highly significant increases in the prostate cancer patients than in the healthy individuals. Furthermore, the means of omentin-1 (31.6±12.8 vs. 23.5±14.1) and total oxidant stress (22.4±10.6 vs. 9.1±3.6) were highly significant increases in patients with prostate cancer than in healthy individuals. In contrast, the means of irisin (343.5±240.2 vs. 716.4±142.3) and total antioxidant capacity (2.2±1.2 vs. 3.3±1.3) were highly significant decreases in patients with prostate cancer than in healthy individuals. No significant relationship was demonstrated between all parameters in the two groups under study.
Conclusion: The study findings indicate that irisin and omentin-1 could serve as biomarkers for predicting prostate cancer.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2024/03/19 | Accepted: 2024/06/9 | Published: 2024/10/22
Received: 2024/03/19 | Accepted: 2024/06/9 | Published: 2024/10/22
References
1. Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, et al. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020;203(4):706-712. [DOI:10.1097/JU.0000000000000617] [PMID] []
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. [DOI:10.3322/caac.21660] [PMID]
3. Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, et al. Epidemiology, Staging and Management of Prostate Cancer. Med Sci (Basel). 2020;8(3):28. [DOI:10.3390/medsci8030028] [PMID] []
4. Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, Goodwin PJ. Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. J Natl Cancer Inst. 2021;113(11):1465-1475. [DOI:10.1093/jnci/djab023] [PMID] []
5. Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci (Lond). 2021;135(6):731-752. [DOI:10.1042/CS20200895] [PMID] []
6. Song YC, Lee SE, Jin Y, Park HW, Chun KH, Lee HW. Classifying the Linkage between Adipose Tissue Inflammation and Tumor Growth through Cancer-Associated Adipocytes. Mol Cells. 2020;43(9):763-773.
7. Fryczkowski M, Bułdak RJ, Hejmo T, Kukla M, Żwirska-Korczala K. Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer. Dis Markers. 2018;2018:3852401. [DOI:10.1155/2018/3852401] [PMID] []
8. Salman Jasim H, Farooq Altaie A, Touma Saloum W, Hussein Ali A. Comparative Study of New Biomarkers in Iraqi DM2 with and without Complications. Rep Biochem Mol Biol. 2022;11(3):400-404. [DOI:10.52547/rbmb.11.3.400] [PMID] []
9. Yano N, Zhao YT, Zhao TC. The Physiological Role of Irisin in the Regulation of Muscle Glucose Homeostasis. Endocrines. 2021;2(3):266-283. [DOI:10.3390/endocrines2030025] [PMID] []
10. Provatopoulou X, Georgiou GP, Kalogera E, Kalles V, Matiatou MA, Papapanagiotou I, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15:898. [DOI:10.1186/s12885-015-1898-1] [PMID] []
11. Tekin S, Erden Y, Sandal S, Yilmaz B. Is irisin an anticarcinogenic peptide?. Med Sci. 2015;4(2):2172-2180. [DOI:10.5455/medscience.2014.03.8210]
12. Li Z, Liu B, Zhao D, Wang B, Liu Y, Zhang Y, et al. Omentin-1 prevents cartilage matrix destruction by regulating matrix metalloproteinases. Biomed Pharmacother. 2017;92:265-269. [DOI:10.1016/j.biopha.2017.05.059] [PMID]
13. Zhang YY, Zhou LM. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur J Pharmacol. 2013;698(1-3):137-44. [DOI:10.1016/j.ejphar.2012.11.016] [PMID]
14. Shen XD, Zhang L, Che H, Zhang YY, Yang C, Zhou J, Liang CZ. Circulating levels of adipocytokine omentin-1 in patients with renal cell cancer. Cytokine. 2016;77:50-5. [DOI:10.1016/j.cyto.2015.09.004] [PMID]
15. Hajam YA, Rani R, Ganie SY, Sheikh TA, Javaid D, Qadri SS, et al. Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives. Cells. 2022;11(3):552. [DOI:10.3390/cells11030552] [PMID] []
16. Ahmadzadeh A, Khodayar MJ, Salehcheh M, Nazari Khorasgani Z, Matin M. Evaluation of the Total Oxidant Status to the Antioxidant Capacity Ratio as a Valuable Biomarker in Breast Cancer Patients. Rep Biochem Mol Biol. 2023;12(2):277-283. [DOI:10.61186/rbmb.12.2.277] [PMID] []
17. Mazur-Bialy AI, Kozlowska K, Pochec E, Bilski J, Brzozowski T. Myokine irisin-induced protection against oxidative stress in vitro. Involvement of heme oxygenase-1 and antioxidazing enzymes superoxide dismutase-2 and glutathione peroxidase. J Physiol Pharmacol. 2018;69(1):117-125.
18. Song J, Zhang H, Sun Y, Guo R, Zhong D, Xu R, Song M. Omentin-1 protects renal function of mice with type 2 diabetic nephropathy via regulating miR-27a-Nrf2/Keap1 axis. Biomed Pharmacother. 2018;107:440-446.
https://doi.org/10.1016/j.biopha.2018.08.002 [DOI:10.1016/j.biopha.2017.12.039] [PMID]
19. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009;27(21):3459-64. [DOI:10.1200/JCO.2008.20.4669] [PMID] []
20. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103-11. [DOI:10.1016/j.clinbiochem.2005.08.008] [PMID]
21. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277-85. [DOI:10.1016/j.clinbiochem.2003.11.015] [PMID]
22. Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007;52(1):46-53. [DOI:10.1016/j.eururo.2007.03.054] [PMID]
23. Oh B, Figtree G, Costa D, Eade T, Hruby G, Lim S, et al. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int. 2016;4(3):71-87. [DOI:10.1016/j.prnil.2016.05.002] [PMID] []
24. Aslan R, Alp HH, Eryılmaz R, Huyut Z, Sevim M, Araz Ş, et al. Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study. Asian Pac J Cancer Prev. 2020;21(2):505-509. [DOI:10.31557/APJCP.2020.21.2.505] [PMID] []
25. Tumer AA, Rashid FA. The Relationship between Circulating Irisin and Oxidative Stress in Gastric and Colorectal Cancer Patients. Asian Pac J Cancer Prev. 2022;23(8):2649-2654. [DOI:10.31557/APJCP.2022.23.8.2649] [PMID] []
26. Zhang ZP, Zhang XF, Li H, Liu TJ, Zhao QP, Huang LH, et al. Serum irisin associates with breast cancer to spinal metastasis. Medicine (Baltimore). 2018;97(17):e0524. [DOI:10.1097/MD.0000000000010524] [PMID] []
27. Aydin S, Kuloglu T, Ozercan MR, Albayrak S, Aydin S, Bakal U, et al. Irisin immunohistochemistry in gastrointestinal system cancers. Biotech Histochem. 2016;91(4):242-50. [DOI:10.3109/10520295.2015.1136988] [PMID]
28. Kuloglu T, Celik O, Aydin S, Hanifi Ozercan I, Acet M, Aydin Y, et al. Irisin immunostaining characteristics of breast and ovarian cancer cells. Cell Mol Biol (Noisy-le-grand). 2016;62(8):40-4.
29. Zhang J, Ke M, Ren Y, Bi J, Du Z, Zhang M, et al. Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma. Dis Markers. 2019;2019:9850191. [DOI:10.1155/2019/9850191] [PMID] []
30. Pinkowska A, Podhorska-Okołów M, Dzięgiel P, Nowińska K. The Role of Irisin in Cancer Disease. Cells. 2021;10(6):1479. [DOI:10.3390/cells10061479] [PMID] []
31. Tsiani E, Tsakiridis N, Kouvelioti R, Jaglanian A, Klentrou P. Current Evidence of the Role of the Myokine Irisin in Cancer. Cancers (Basel). 2021;13(11):2628. [DOI:10.3390/cancers13112628] [PMID] []
32. Saeedi Sadr A, Ehteram H, Seyed Hosseini E, Alizadeh Zarei M, Hassani Bafrani H, Haddad Kashani H. The Effect of Irisin on Proliferation, Apoptosis, and Expression of Metastasis Markers in Prostate Cancer Cell Lines. Oncol Ther. 2022;10(2):377-388.
https://doi.org/10.1007/s40487-022-00194-4 [DOI:10.1007/s40487-022-00199-z] [PMID] []
33. Phan T, Weber A, Bryce AH, Kuang Y. The prognostic value of androgen to PSA ratio in predictive modeling of prostate cancer. Med Hypotheses. 2023;176:111084. [DOI:10.1016/j.mehy.2023.111084]
34. Siech C, Rutz J, Maxeiner S, Grein T, Sonnenburg M, Tsaur I, et al. Insulin-like Growth Factor-1 Influences Prostate Cancer Cell Growth and Invasion through an Integrin α3, α5, αV, and β1 Dependent Mechanism. Cancers (Basel). 2022;14(2):363. [DOI:10.3390/cancers14020363] [PMID] []
35. Andò S, Simões BM. Editorial: Adipokines and hormone-dependent cancers. Front Endocrinol (Lausanne). 2023;14:1340171. [DOI:10.3389/fendo.2023.1340171] [PMID] []
36. Dec P, Poniewierska-Baran A, Modrzejewski A, Pawlik A. The Role of Omentin-1 in Cancers Development and Progression. Cancers (Basel). 2023;15(15):3797. [DOI:10.3390/cancers15153797] [PMID] []
37. Zhou L, He W, Wang W, Zhou D. Altered circulating levels of adipokine omentin-1 in patients with prostate cancer. Onco Targets Ther. 2019;12:3313-3319. [DOI:10.2147/OTT.S197507] [PMID] []
38. Zhang YY, Zhou LM. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur J Pharmacol. 2013;698(1-3):137-44. [DOI:10.1016/j.ejphar.2012.11.016] [PMID]
39. Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J Am Coll Cardiol. 2014;63(24):2722-33. [DOI:10.1016/j.jacc.2014.03.032] [PMID]
40. Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008;452(7187):646-9. [DOI:10.1038/nature06778] [PMID] []
41. Bozkurt A, Gürsul C, Aydin M, Sayar İ, Karabakan M, Çikman A. The evaluation of oxidative stress parameters in the benign prostatic hyperplasia, prostatitis and prostate cancer. Ortadogu Med. J. 2019;11(3):315-321. [DOI:10.21601/ortadogutipdergisi.462457]
42. Freitas M, Baldeiras I, Proença T, Alves V, Mota-Pinto A, Sarmento-Ribeiro A. Oxidative stress adaptation in aggressive prostate cancer may be counteracted by the reduction of glutathione reductase. FEBS Open Bio. 2012;2:119-28. [DOI:10.1016/j.fob.2012.05.001] [PMID] []
43. White EZ, Pennant NM, Carter JR, Hawsawi O, Odero-Marah V, Hinton CV. Serum deprivation initiates adaptation and survival to oxidative stress in prostate cancer cells. Sci Rep. 2020;10(1):12505. [DOI:10.1038/s41598-020-68668-x] [PMID] []
44. Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014;63(10):1265-71. [DOI:10.1016/j.metabol.2014.06.001] [PMID] []
45. Panagiotou G, Triantafyllidou S, Tarlatzis BC, Papakonstantinou E. Serum Levels of Irisin and Omentin-1 in Breast Neoplasms and Their Association with Tumor Histology. Int J Endocrinol. 2021;2021:6656671. [DOI:10.1155/2021/6656671] [PMID] []
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
